Lastly, the effectiveness of checkpoint inhibitors in prostate cancer, such as PD-L1, PD1, and CTLA-4 inhibitors, have been very poor despite multiple attempts to exploit these agents in prostate cancer. This evidence concerns the gene CTLA4 and prostate cancer.